Drug intelligence / Profile preview

Betrat

Development stage: Unknown
Lead developer: Myralis
Modality: Small Molecules
Administration: Oral

Overview

**Betrat** is a prescription fixed-dose oral vitamin B-complex product from Myralis containing thiamine nitrate, pyridoxine hydrochloride, and cyanocobalamin. It is indicated as an adjunctive treatment for nociceptive pain and impaired mobility associated with osteoarthritis. The product supplies high doses of vitamins B1, B6, and B12; its labeling describes analgesic effects in neuralgia and support for recovery of injured nerve fibers, while the vitamins also serve essential metabolic and neurologic functions. ([myralis.com.br](https://myralis.com.br/betrat))

Brand names: Betrat
Other names: cyanocobalamin + pyridoxine hydrochloride + thiamine nitrate

Beyond the preview

Go deeper on Betrat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Betrat.

Explore the full profile